Sandoz Group AG
A global leader in generic and biosimilar medicines.
SDZ | SW
Overview
Corporate Details
- ISIN(s):
- CH1243598427 (+2 more)
- LEI:
- 5493000JWK6XWFEUD320
- Country:
- Switzerland
- Address:
- Suurstoffi 14, 6343 Rotkreuz
- Website:
- https://www.sandoz.com/
- Sector:
- Manufacturing
Description
Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-08 07:00 |
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserti…
|
English | 16.1 KB | ||
| 2025-12-08 01:00 |
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserti…
|
English | 13.8 KB | ||
| 2025-12-01 07:00 |
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment…
|
English | 31.0 KB | ||
| 2025-12-01 01:00 |
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment…
|
English | 27.8 KB | ||
| 2025-11-24 07:00 |
Sandoz launches Afqlir (aflibercept) in Europe, providing affordable treatment …
|
English | 29.1 KB | ||
| 2025-11-24 01:00 |
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment…
|
English | 27.3 KB | ||
| 2025-11-17 07:00 |
Sandoz launches TYRUKO (natalizumab-sztn) in US, as first and only multiple scl…
|
English | 33.9 KB | ||
| 2025-11-12 07:35 |
Sandoz signs global license agreement to commercialize breast cancer biosimilar…
|
English | 22.7 KB | ||
| 2025-11-12 01:00 |
Sandoz signs global license agreement to commercialize breast cancer biosimilar…
|
English | 20.1 KB | ||
| 2025-11-04 22:05 |
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire…
|
English | 18.5 KB | ||
| 2025-11-04 01:00 |
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire…
|
English | 15.7 KB | ||
| 2025-10-30 07:00 |
Sandoz delivers a further acceleration in sales growth; full-year margin guidan…
|
English | 155.3 KB | ||
| 2025-10-30 01:00 |
Sandoz delivers a further acceleration in sales growth; full-year margin guidan…
|
English | 156.9 KB | ||
| 2025-09-09 07:00 |
Sandoz reaches agreement with Regeneron, resolving all patent litigation relate…
|
English | 20.4 KB | ||
| 2025-09-09 02:00 |
Sandoz reaches agreement with Regeneron, resolving all patent litigation relate…
|
English | 17.1 KB |
Automate Your Workflow. Get a real-time feed of all Sandoz Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sandoz Group AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sandoz Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-02 | N/A | Non-Executive member | Buy | None | 251,343.62 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 270,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 260,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 230,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 202,500.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 187,500.00 CHF |
| 2024-08-21 | N/A | Non-Executive member | Buy | None | 429,855.85 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 130,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 115,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 62,500.00 CHF |
Peer Companies
